指南与共识MDS 与骨髓增殖性肿瘤

910例系统性肥大细胞增多症患者:国际共识分类在梅奥联盟预后系统背景下的预后贡献

Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System.
指南 / 共识 · Am J Hematol · 2025-07-03

该研究纳入1968至2024年在梅奥诊所就诊的910例系统性肥大细胞增多症(SM)患者,比较国际共识分类(ICC)与WHO-HAEM5分类的预后价值,并评估ICC形态学亚型在梅奥联盟预后系统(MAPS)基础上的独立预后贡献。ICC定义的重度SM(MCL)中位总生存期0.08年,显著短于SM伴髓系肿瘤(SM-AMN)的2.0年(P<0.01);多变量分析证实ICC形态学亚型与MAPS风险变量(年龄>60岁、贫血、碱性磷酸酶>ULN、血小板<150×10^9/L)均独立预后(P均<0.03),而WHO-HAEM5亚型无此独立贡献。

要点

  • ICC定义的重度SM(MCL)中位总生存期0.08年,显著短于SM-AMN的2.0年(P<0.01)。
  • ICC定义的SM-AMN与SM伴淋系肿瘤(SM-ALN)总生存期差异显著(HR 3.4;P<0.01)。
  • ICC形态学亚型与MAPS风险变量均为独立预后因素(P均<0.03),WHO-HAEM5亚型则否。

核心结论

  • ICC分类对SM的预后判断比WHO-HAEM5更准确,并强化了形态学在当前临床和分子风险模型中的预后贡献。

研究设计与样本

  • 研究纳入1968至2024年在梅奥诊所就诊的910例SM患者,主要目的是在MAPS背景下检验ICC的预后贡献。
  • WHO-HAEM5亚型包括惰性/冒烟型SM(ISM/SSM;N=518)、SM伴另一血液肿瘤(SM-AHN;N=273,含髓系和淋系肿瘤)、侵袭性SM(ASM;N=106)和WHO定义的重度SM(MCL;N=13,含成熟和未成熟形态肥大细胞)。
  • ICC亚型与WHO-HAEM5基本相似,但SM-AHN被替换为SM伴另一髓系肿瘤(SM-AMN;N=235),WHO定义MCL被替换为ICC定义MCL(N=8,仅含未成熟形态肥大细胞)。

主要发现

  • WHO定义MCL(中位1.8年)与SM-AHN(中位2.3年)的总生存期相似(P=0.3)。
  • ICC定义MCL(中位0.08年)与SM-AMN(中位2.0年)的总生存期差异显著(P<0.01)。
  • ICC定义SM-AMN与SM伴淋系肿瘤(SM-ALN;中位8.1年)的总生存期差异显著(HR 3.4;P<0.01)。
  • 多变量分析证实ICC形态学亚型和MAPS风险变量(年龄>60岁、贫血、碱性磷酸酶>ULN、血小板<150×10^9/L)均独立预后(P均<0.03),WHO-HAEM5亚型则无此独立贡献。
  • 将突变信息加入多变量模型后,贫血被剔除,ASXL1(P<0.01)、SRSF2(P=0.01)和NRAS(P=0.01)突变作为额外风险因素纳入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current study includes 910 patients with systemic mastocytosis (SM) seen at the Mayo Clinic from 1968 to 2024. The primary objective was to examine the prognostic contribution of the International Consensus Classification (ICC), in the context of the Mayo Alliance Prognostic System (MAPS) for SM. World Health Organization classification (WHO-HAEM5) subcategories included (i) indolent/smoldering SM (ISM/SSM; N = 518), (ii) SM associated with another hematological neoplasm (SM-AHN; N = 273), with the latter including both myeloid and lymphoid neoplasms, (iii) aggressive SM (ASM; N = 106), and (iv) WHO-defined mast cell leukemia (MCL; N = 13), which included mast cells with both "mature" and "immature" morphology. The ICC-defined subcategories were mostly similar with the exception that SM-AHN was replaced by SM associated with another myeloid neoplasm (SM-AMN; N = 235) and WHO-defined MCL was replaced by ICC-defined MCL (N = 8), which included only those with immature MC morphology. Overall survival (OS) was similar between WHO-defined MCL (median 1.8 years) vs. SM-AHN (median 2.3 years; p = 0.3) but significantly different between ICC-defined MCL (median 0.08 years) vs. SM-AMN (median 2.0 years; p < 0.01). Significant difference in OS was also apparent between ICC-defined SM-AMN and SM associated with lymphoid neoplasm (SM-ALN; median 8.1 years; HR 3.4; p < 0.01). Multivariable analysis confirmed the inter-independent prognostic contributions of both ICC-defined morphologic subcategories and MAPS risk variables, including age > 60 years, anemia, alkaline phosphatase > ULN, and platelet count < 150 × 109/L (p < 0.03 in all instances); the same was not true for WHO-HAEM5-defined SM subcategories. The addition of mutational information into the multivariable model resulted in ousting anemia and inclusion of ASXL1 (p < 0.01), SRSF2 (p = 0.01), and NRAS (p = 0.01) mutations as additional risk factors. Classification of SM by ICC is prognostically more accurate, compared to WHO-HAEM5, and strengthens the prognostic contribution of morphology to current clinical and molecular risk models.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Aperna F, Abdelmagid MG, Kumar M, et al. Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System. Am J Hematol. 2025. PMID: 40607735. doi:10.1002/ajh.27764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。